Processa Pharmaceuticals Net Income
| PCSA Stock | USD 2.45 0.12 5.15% |
As of the 11th of February 2026, Processa Pharmaceuticals holds the Coefficient Of Variation of (3,853), variance of 334.62, and Risk Adjusted Performance of (0.01). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Processa Pharmaceuticals, as well as the relationship between them.
Processa Pharmaceuticals Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -10.7 M | -11.2 M | |
| Net Loss | -10.7 M | -11.2 M | |
| Net Loss | -10.3 M | -9.8 M | |
| Net Loss | (87.14) | (91.49) | |
| Net Income Per E B T | 1.10 | 1.12 |
Processa | Net Income | Build AI portfolio with Processa Stock |
Analyzing Processa Pharmaceuticals's Net Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Income has evolved provides context for assessing Processa Pharmaceuticals's current valuation and future prospects.
Latest Processa Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Processa Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Processa Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Processa Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Processa Pharmaceuticals' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Processa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (11.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Processa Net Income Regression Statistics
| Arithmetic Mean | (7,620,576) | |
| Coefficient Of Variation | (95.61) | |
| Mean Deviation | 5,809,715 | |
| Median | (3,765,047) | |
| Standard Deviation | 7,286,004 | |
| Sample Variance | 53.1T | |
| Range | 27.3M | |
| R-Value | (0.68) | |
| Mean Square Error | 30.2T | |
| R-Squared | 0.47 | |
| Significance | 0 | |
| Slope | (984,776) | |
| Total Sum of Squares | 849.4T |
Processa Net Income History
Other Fundumenentals of Processa Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Processa Pharmaceuticals Net Income component correlations
Processa Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Processa Pharmaceuticals is extremely important. It helps to project a fair market value of Processa Stock properly, considering its historical fundamentals such as Net Income. Since Processa Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Processa Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Processa Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.
Processa Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Processa Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Processa Pharmaceuticals.
| 11/13/2025 |
| 02/11/2026 |
If you would invest 0.00 in Processa Pharmaceuticals on November 13, 2025 and sell it all today you would earn a total of 0.00 from holding Processa Pharmaceuticals or generate 0.0% return on investment in Processa Pharmaceuticals over 90 days. Processa Pharmaceuticals is related to or competes with Briacell Therapeutics, Curis, Palisade Bio, Hoth Therapeutics, Moleculin Biotech, Athira Pharma, and Allarity Therapeutics. Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products ... More
Processa Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Processa Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Processa Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 164.28 | |||
| Value At Risk | (14.08) | |||
| Potential Upside | 11.68 |
Processa Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Processa Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Processa Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Processa Pharmaceuticals historical prices to predict the future Processa Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (2.64) | |||
| Treynor Ratio | 3.07 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Processa Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Processa Pharmaceuticals February 11, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 3.08 | |||
| Mean Deviation | 8.31 | |||
| Coefficient Of Variation | (3,853) | |||
| Standard Deviation | 18.29 | |||
| Variance | 334.62 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (2.64) | |||
| Treynor Ratio | 3.07 | |||
| Maximum Drawdown | 164.28 | |||
| Value At Risk | (14.08) | |||
| Potential Upside | 11.68 | |||
| Skewness | 4.38 | |||
| Kurtosis | 32.71 |
Processa Pharmaceuticals Backtested Returns
Processa Pharmaceuticals maintains Sharpe Ratio (i.e., Efficiency) of -0.0212, which implies the firm had a -0.0212 % return per unit of risk over the last 3 months. Processa Pharmaceuticals exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Processa Pharmaceuticals' Coefficient Of Variation of (3,853), risk adjusted performance of (0.01), and Variance of 334.62 to confirm the risk estimate we provide. The company holds a Beta of -0.16, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Processa Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Processa Pharmaceuticals is likely to outperform the market. At this point, Processa Pharmaceuticals has a negative expected return of -0.4%. Please make sure to check Processa Pharmaceuticals' accumulation distribution, and the relationship between the potential upside and day median price , to decide if Processa Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.70 |
Good predictability
Processa Pharmaceuticals has good predictability. Overlapping area represents the amount of predictability between Processa Pharmaceuticals time series from 13th of November 2025 to 28th of December 2025 and 28th of December 2025 to 11th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Processa Pharmaceuticals price movement. The serial correlation of 0.7 indicates that around 70.0% of current Processa Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.7 | |
| Spearman Rank Test | 0.49 | |
| Residual Average | 0.0 | |
| Price Variance | 0.18 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Processa Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Processa Pharmaceuticals reported net income of (11.85 Million). This is 103.47% lower than that of the Biotechnology sector and 116.92% lower than that of the Health Care industry. The net income for all United States stocks is 102.08% higher than that of the company.
Processa Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Processa Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Processa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Processa Pharmaceuticals by comparing valuation metrics of similar companies.Processa Pharmaceuticals is currently under evaluation in net income category among its peers.
Processa Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Processa Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Processa Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Processa Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Processa Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Processa Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Processa Pharmaceuticals' value.| Shares | Sbi Securities Co Ltd | 2025-06-30 | 12.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 2.0 | Miracle Mile Advisors, Inc. | 2025-06-30 | 0.0 | Armistice Capital, Llc | 2025-06-30 | 0.0 | Hrt Financial Llc | 2025-03-31 | 0.0 | Virtu Financial Llc | 2025-06-30 | 104.7 K | Ubs Group Ag | 2025-06-30 | 64.6 K | Alpine Partners Vi, Llc | 2025-06-30 | 53.4 K | Geode Capital Management, Llc | 2025-06-30 | 50.6 K | Cubist Systematic Strategies, Llc | 2025-06-30 | 41.8 K | Vanguard Group Inc | 2025-06-30 | 24.4 K |
Processa Fundamentals
| Return On Equity | -2.71 | ||||
| Return On Asset | -1.3 | ||||
| Current Valuation | (1.03 M) | ||||
| Shares Outstanding | 2.27 M | ||||
| Shares Owned By Insiders | 10.76 % | ||||
| Shares Owned By Institutions | 9.02 % | ||||
| Number Of Shares Shorted | 29.97 K | ||||
| Price To Book | 0.88 X | ||||
| EBITDA | (12.05 M) | ||||
| Net Income | (11.85 M) | ||||
| Cash And Equivalents | 12.06 M | ||||
| Cash Per Share | 0.76 X | ||||
| Total Debt | 73.51 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 8.89 X | ||||
| Book Value Per Share | 2.76 X | ||||
| Cash Flow From Operations | (11.25 M) | ||||
| Short Ratio | 0.01 X | ||||
| Earnings Per Share | (29.51) X | ||||
| Price To Earnings To Growth | (0.12) X | ||||
| Target Price | 25.0 | ||||
| Number Of Employees | 10 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 5.28 M | ||||
| Total Asset | 3.23 M | ||||
| Retained Earnings | (87.22 M) | ||||
| Working Capital | 340.99 K | ||||
| Net Asset | 3.23 M |
About Processa Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Processa Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Processa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Processa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.